Videos

Breast Cancer

Alexander E. Perl, MD, discusses results from the phase III ADMIRAL trial, which demonstrated a significant improvement in overall survival in patients with <em>FLT3</em>-mutated acute myeloid leukemia treated with the FLT3 inhibitor gilteritinib.

Nathan H. Fowler, MD, discusses the latest addition to the treatment landscape for marginal zone lymphoma.

Pashtoon M. Kasi, MD, MBBS, MS, discusses how genetic testing is underutilized in colorectal cancer, despite its ability to guide treatment dosing and adjustment based on the mutations or variations within a patient.

William J. Gradishar, MD, discusses the NCCN guidelines in regard to selecting molecular assays for patients with breast cancer. Currently, there are 3 available assays that clinicians can order: 21-gene, 50-gene, and 70-gene assays.

Frederick L. Locke, MD, discusses how chimeric antigen receptor (CAR) T-cell therapies have evolved over the last 30 years of research in the field of hematologic malignancies.

Saad Z. Usmani, MD, FACP, chief of&nbsp;Plasma&nbsp;Cell Disorder, director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, discusses how to manage early relapse in multiple myeloma.

Peter Grivas, MD, PhD, discusses the next steps necessary for the treatment landscape of advanced urothelial cancer to evolve.

<p>David S. Hong, MD, discusses the results from the phase II innovaTV 201 trial looking at the antibody-drug conjugate tisotumab vedotin in patients with metastatic&nbsp; or recurrent cervical cancer.</p>

Asymptomatic Relapsed Multiple Myeloma

Edwin M. Posadas, MD, medical director, Urologic Oncology Program, co-director, Translational Oncology Program, associate professor, Medicine, Cedars-Sinai Medical Center, discusses key takeaways from the ARAMIS trial of darolutamide in high-risk nonmetastatic castration-resistant prostate cancer.

Mark T. Fleming, MD, medical oncologist, Virginia Oncology Associates, The US Oncology Research, discusses exciting data seen with antiandrogen agents for the treatment of prostate cancer.

Kevin Staveley-O&rsquo;Carroll, MD, PhD, discusses one of the challenges in treating patients with hepatocellular carcinoma and shares what he thinks are the next steps in overcoming this challenge.

Alexander E. Drilon, MD, discusses the next steps for LOXO-292 in 2 subsets of patients: those with RET fusion-positive cancers and <em>RET</em>-mutant medullary thyroid cancers.

Ali McBride, PharmD, MS, BCOP, discusses the theme for his presidency: Collaborate. Educate. Compensate: A Prescription for Sustainable Cancer Care Delivery.<br /> &nbsp;